SRI31277

Transforming Growth Factor beta antagonist

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Murphy-Ullrich, Joanne E: 2 articles (01/2022 - 03/2016)
2.	Suto, Mark J: 2 articles (01/2022 - 03/2016)
3.	Yang, Yang: 2 articles (01/2022 - 03/2016)
4.	Gowda, Pramod S: 1 article (01/2022)
5.	Javed, Amjad: 1 article (01/2022)
6.	Li, Juan: 1 article (01/2022)
7.	Lu, Yun: 1 article (01/2022)
8.	Trotter, Timothy N: 1 article (01/2022)
9.	Xu, Xiaoxuan: 1 article (01/2022)
10.	Zhang, Chao: 1 article (01/2022)

1.	Neoplasms (Cancer) 03/01/2016 - "SRI31277 reduced tumor burden in the immune competent 5TGM1 myeloma model. " 01/01/2022 - "In multiple myeloma tumor-bearing OB-Runx2-/- mice, treatment with SRI31277, an antagonist of thrombospondin-1 (TSP-1)-mediated TGFβ1 activation, reversed the BM immunosuppression and significantly reduced tumor burden. " 01/01/2022 - "Furthermore, treatment with SRI31277 combined with bortezomib alleviated multiple myeloma cell resistance to bortezomib-induced apoptosis caused by OB-Runx2 deficiency in cocultured cells and produced a synergistic effect on tumor burden in OB-Runx2-/- mice. " 03/01/2016 - "SRI31277 was as effective as dexamethasone or bortezomib, and SRI31277 combined with bortezomib showed greater tumor reduction than either agent alone. "
2.	Multiple Myeloma 01/01/2022 - "In multiple myeloma tumor-bearing OB-Runx2-/- mice, treatment with SRI31277, an antagonist of thrombospondin-1 (TSP-1)-mediated TGFβ1 activation, reversed the BM immunosuppression and significantly reduced tumor burden. " 01/01/2022 - "Furthermore, treatment with SRI31277 combined with bortezomib alleviated multiple myeloma cell resistance to bortezomib-induced apoptosis caused by OB-Runx2 deficiency in cocultured cells and produced a synergistic effect on tumor burden in OB-Runx2-/- mice. "